ArticleJournal of veterinary internal medicine2026
Assessment of gastrointestinal health and the coagulation system in dogs with right-sided heart disease: an exploratory study.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundRight-sided heart disease (RHD) affects gastrointestinal function and hemostasis. HYPOTHESIS/
objectivesDogs with progressively severe RHD have impaired gastrointestinal function and altered hemostasis. ANIMALS: Eighteen client-owned dogs with RHD; group 1: 6 dogs without hepatic venous congestion, group 2: 6 dogs with hepatic venous congestion but no ascites, and group 3: 6 dogs with ascites.
methodsProspective, cross-sectional, exploratory study. Dogs underwent routine blood, urine, and fecal testing, measures of gastrointestinal health, coagulation testing, C-reactive protein (CRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and comprehensive echocardiography.
resultsRight atrial area higher from groups 1 to 3 (1.34 ± 0.66, 2.48 ± 1.33, 3.1 ± 0.93 cm2/kg0.71; P = .02). NT-proBNP (median; range) higher across group 1 (821; 493-3016 pmol/L), group 2 (1694; 1125-8117 pmol/L), and group 3 (5165; 3492-10 000 pmol/L) (P = .006). Measures of gastrointestinal dysfunction including serum methylmalonic acid (group 1 = 857.5 ± 322.6; group 2 = 1031.1 ± 222.5; and group 3 = 1460.5 ± 516.3 nmol/L; P = .037) and intestinal fatty acid binding protein (group 1 median = 9.3, range = 5.6-11.5; group 2 = 10.1, 8.0-20.4; and group 3 = 13.8, 10.3-17.5 ng/mL) were worse in more severely affected dogs (P = .032). Hyperfibrinolysis was observed with worsening RHD (none in group 1, 2 in group 2, and 3 in group 3). Activated partial thromboplastin time was higher with disease severity. No difference was detected among groups in cobalamin, folate, or CRP (all P > .05). CONCLUSIONS AND CLINICAL IMPORTANCE: Clinicians should be aware of derangements within the gut-heart axis and coagulation system when managing dogs with RHD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.